Your browser doesn't support javascript.
loading
Global hyperactivation of enhancers stabilizes human and mouse naive pluripotency through inhibition of CDK8/19 Mediator kinases.
Lynch, Cian J; Bernad, Raquel; Martínez-Val, Ana; Shahbazi, Marta N; Nóbrega-Pereira, Sandrina; Calvo, Isabel; Blanco-Aparicio, Carmen; Tarantino, Carolina; Garreta, Elena; Richart-Ginés, Laia; Alcazar, Noelia; Graña-Castro, Osvaldo; Gómez-Lopez, Gonzalo; Aksoy, Irene; Muñoz-Martín, Maribel; Martinez, Sonia; Ortega, Sagrario; Prieto, Susana; Simboeck, Elisabeth; Camasses, Alain; Stephan-Otto Attolini, Camille; Fernandez, Agustin F; Sierra, Marta I; Fraga, Mario F; Pastor, Joaquin; Fisher, Daniel; Montserrat, Nuria; Savatier, Pierre; Muñoz, Javier; Zernicka-Goetz, Magdalena; Serrano, Manuel.
Afiliação
  • Lynch CJ; Tumour Suppression Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Bernad R; Cellular Plasticity and Disease Group, Institute for Research in Biomedicine (IRB Barcelona), Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.
  • Martínez-Val A; Tumour Suppression Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Shahbazi MN; Cellular Plasticity and Disease Group, Institute for Research in Biomedicine (IRB Barcelona), Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.
  • Nóbrega-Pereira S; ProteoRed-ISCIII Proteomics Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Calvo I; Mammalian Embryo and Stem Cell Group, Department of Physiology, Development and Neuroscience, University of Cambridge, Cambridge, UK.
  • Blanco-Aparicio C; MRC Laboratory of Molecular Biology, Biomedical Campus, Cambridge, UK.
  • Tarantino C; Department of Medical Sciences and Institute of Biomedicine (iBiMED), University of Aveiro, Aveiro, Portugal.
  • Garreta E; Tumour Suppression Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Richart-Ginés L; Cellular Plasticity and Disease Group, Institute for Research in Biomedicine (IRB Barcelona), Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.
  • Alcazar N; Experimental Therapeutics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Graña-Castro O; Pluripotency for Organ Regeneration, Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute for Science and Technology (BIST), Barcelona, Spain.
  • Gómez-Lopez G; Pluripotency for Organ Regeneration, Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute for Science and Technology (BIST), Barcelona, Spain.
  • Aksoy I; Maintenance of Transcriptional Repression by Polycomb Proteins, Institut Curie, Paris, France.
  • Muñoz-Martín M; Tumour Suppression Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Martinez S; Cellular Plasticity and Disease Group, Institute for Research in Biomedicine (IRB Barcelona), Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.
  • Ortega S; Bioinformatics Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Prieto S; Bioinformatics Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Simboeck E; Stem Cell and Brain Research Institute, Univ Lyon, Université Lyon 1, INSERM U1208, Bron, France.
  • Camasses A; Tumour Suppression Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Stephan-Otto Attolini C; Cellular Plasticity and Disease Group, Institute for Research in Biomedicine (IRB Barcelona), Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.
  • Fernandez AF; Experimental Therapeutics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Sierra MI; Transgenic Mice Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Fraga MF; IGMM, University of Montpellier, CNRS, Inserm, Montpellier, France.
  • Pastor J; IGMM, University of Montpellier, CNRS, Inserm, Montpellier, France.
  • Fisher D; IGMM, University of Montpellier, CNRS, Inserm, Montpellier, France.
  • Montserrat N; Bioinformatics-Biostatistics Unit, Institute for Research in Biomedicine (IRB Barcelona), Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.
  • Savatier P; Cancer Epigenetics and Nanomedicine Laboratory, Nanomaterials and Nanotechnology Research Center (CINN-CSIC), Institute of Oncology of Asturias (IUOPA), ISPA-Hospital Universitario Central de Asturias (HUCA), Universidad de Oviedo, Oviedo, Spain.
  • Muñoz J; Cancer Epigenetics and Nanomedicine Laboratory, Nanomaterials and Nanotechnology Research Center (CINN-CSIC), Institute of Oncology of Asturias (IUOPA), ISPA-Hospital Universitario Central de Asturias (HUCA), Universidad de Oviedo, Oviedo, Spain.
  • Zernicka-Goetz M; Cancer Epigenetics and Nanomedicine Laboratory, Nanomaterials and Nanotechnology Research Center (CINN-CSIC), Institute of Oncology of Asturias (IUOPA), ISPA-Hospital Universitario Central de Asturias (HUCA), Universidad de Oviedo, Oviedo, Spain.
  • Serrano M; Experimental Therapeutics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
Nat Cell Biol ; 22(10): 1223-1238, 2020 10.
Article em En | MEDLINE | ID: mdl-32989249
ABSTRACT
Pluripotent stem cells (PSCs) transition between cell states in vitro, reflecting developmental changes in the early embryo. PSCs can be stabilized in the naive state by blocking extracellular differentiation stimuli, particularly FGF-MEK signalling. Here, we report that multiple features of the naive state in human and mouse PSCs can be recapitulated without affecting FGF-MEK signalling or global DNA methylation. Mechanistically, chemical inhibition of CDK8 and CDK19 (hereafter CDK8/19) kinases removes their ability to repress the Mediator complex at enhancers. CDK8/19 inhibition therefore increases Mediator-driven recruitment of RNA polymerase II (RNA Pol II) to promoters and enhancers. This efficiently stabilizes the naive transcriptional program and confers resistance to enhancer perturbation by BRD4 inhibition. Moreover, naive pluripotency during embryonic development coincides with a reduction in CDK8/19. We conclude that global hyperactivation of enhancers drives naive pluripotency, and this can be achieved in vitro by inhibiting CDK8/19 kinase activity. These principles may apply to other contexts of cellular plasticity.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Diferenciação Celular / Elementos Facilitadores Genéticos / Quinases Ciclina-Dependentes / Metilação de DNA / Células-Tronco Pluripotentes / Quinase 8 Dependente de Ciclina Limite: Animals / Female / Humans Idioma: En Revista: Nat Cell Biol Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Espanha

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Diferenciação Celular / Elementos Facilitadores Genéticos / Quinases Ciclina-Dependentes / Metilação de DNA / Células-Tronco Pluripotentes / Quinase 8 Dependente de Ciclina Limite: Animals / Female / Humans Idioma: En Revista: Nat Cell Biol Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Espanha